BIO-RAD LABORATORIES -CL B (BIO.B) Stock Price, Quote, News and Overview
NYSE:BIO.B - New York Stock Exchange, Inc. - US0905721082 - Common Stock - Currency: USD
BIO.B Quote, Performance and Key Statistics
NYSE:BIO.B (7/11/2025, 8:04:00 PM)
257.75
+7.67 (+3.07%)
The current stock price of BIO.B is 257.75 USD. In the past month the price decreased by -12.4%. In the past year, price decreased by -57.09%.
BIO.B Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 19.05 | 157.47B | ||
| DHR | DANAHER CORP | 25.96 | 138.43B | ||
| A | AGILENT TECHNOLOGIES INC | 21.02 | 32.24B | ||
| IQV | IQVIA HOLDINGS INC | 13.98 | 27.33B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 29.13 | 24.50B | ||
| WAT | WATERS CORP | 24.37 | 17.27B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 33.63 | 16.04B | ||
| ILMN | ILLUMINA INC | 29.21 | 15.40B | ||
| ICLR | ICON PLC | 10.49 | 11.44B | ||
| RVTY | REVVITY INC | 19.33 | 11.23B | ||
| QGEN | QIAGEN N.V. | 20.95 | 10.43B | ||
| TEM | TEMPUS AI INC | N/A | 10.33B |
Related stock screener links
About BIO.B
Company Profile
Bio-Rad Laboratories, Inc. engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. The company is headquartered in Hercules, California and currently employs 7,700 full-time employees. The firm offers a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components. The company operates through two segments: Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables used for biological research, biopharmaceutical production processes, food testing regimes, and science education. Its Clinical Diagnostics segment designs, manufactures, markets and supports test systems, informatics systems, test kits and specialized quality controls that serve clinical laboratories in the global diagnostics market. These products are sold to hospital laboratories, diagnostic reference laboratories, transfusion laboratories, and physician office laboratories.
Company Info
BIO-RAD LABORATORIES -CL B
1000 Alfred Nobel Dr
Hercules CALIFORNIA US
CEO: Norman Schwartz
Employees: 7700
Phone: 15107247000
BIO-RAD LABORATORIES -CL B / BIO.B FAQ
What is the stock price of BIO-RAD LABORATORIES -CL B today?
The current stock price of BIO.B is 257.75 USD. The price increased by 3.07% in the last trading session.
What is the ticker symbol for BIO-RAD LABORATORIES -CL B stock?
The exchange symbol of BIO-RAD LABORATORIES -CL B is BIO.B and it is listed on the New York Stock Exchange, Inc. exchange.
On which exchange is BIO.B stock listed?
BIO.B stock is listed on the New York Stock Exchange, Inc. exchange.
What is the price forecast or stock price prediction for BIO-RAD LABORATORIES -CL B stock?
11 analysts have analysed BIO.B and the average price target is 369.39 USD. This implies a price increase of 43.31% is expected in the next year compared to the current price of 257.75. Check the BIO-RAD LABORATORIES -CL B stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is BIO-RAD LABORATORIES -CL B worth?
BIO-RAD LABORATORIES -CL B (BIO.B) has a market capitalization of 7.22B USD. This makes BIO.B a Mid Cap stock.
How many employees does BIO-RAD LABORATORIES -CL B have?
BIO-RAD LABORATORIES -CL B (BIO.B) currently has 7700 employees.
What are the support and resistance levels for BIO-RAD LABORATORIES -CL B (BIO.B) stock?
BIO-RAD LABORATORIES -CL B (BIO.B) has a resistance level at 308.41. Check the full technical report for a detailed analysis of BIO.B support and resistance levels.
Is BIO-RAD LABORATORIES -CL B (BIO.B) expected to grow?
The Revenue of BIO-RAD LABORATORIES -CL B (BIO.B) is expected to decline by -2.11% in the next year. Check the estimates tab for more information on the BIO.B EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy BIO-RAD LABORATORIES -CL B (BIO.B) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of BIO.B, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of BIO.B, evaluating the profitability, health, valuation and growth aspects
- BIO-RAD LABORATORIES -CL B (BIO.B) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- BIO-RAD LABORATORIES -CL B (BIO.B) Sales and EPS estimates to see what analysts future expectations are.
- BIO-RAD LABORATORIES -CL B (BIO.B) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- BIO-RAD LABORATORIES -CL B (BIO.B) Insider and Institutional Ownership to learn about the owners and their transactions.
- BIO-RAD LABORATORIES -CL B (BIO.B) Stock Chart to make your own analysis
- BIO-RAD LABORATORIES -CL B (BIO.B) Latest news and press-releases to stay up to date.
Does BIO-RAD LABORATORIES -CL B (BIO.B) stock pay dividends?
BIO.B does not pay a dividend.
When does BIO-RAD LABORATORIES -CL B (BIO.B) report earnings?
BIO-RAD LABORATORIES -CL B (BIO.B) will report earnings on 2025-07-30, after the market close.
What is the Price/Earnings (PE) ratio of BIO-RAD LABORATORIES -CL B (BIO.B)?
The PE ratio for BIO-RAD LABORATORIES -CL B (BIO.B) is 24.41. This is based on the reported non-GAAP earnings per share of 10.56 and the current share price of 257.75 USD. Check the full fundamental report for a full analysis of the valuation metrics for BIO.B.
BIO.B Technical Analysis
BIO.B Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to BIO.B. BIO.B is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average.
BIO.B Financial Highlights
Over the last trailing twelve months BIO.B reported a non-GAAP Earnings per Share(EPS) of 10.56. The EPS decreased by -1.49% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -22.72% | ||
| ROE | -32.4% | ||
| Debt/Equity | 0.18 |
BIO.B Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 76% to BIO.B. The Buy consensus is the average rating of analysts ratings from 11 analysts.
For the next year, analysts expect an EPS growth of -15.61% and a revenue growth -2.11% for BIO.B